Meta-analysis of 14 trials of statins including more than
|
|
- Cori Simpson
- 5 years ago
- Views:
Transcription
1 Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in and Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Larry B. Goldstein, MD; Pierre Amarenco, MD; Marian LaMonte, MD; Steven Gilbert, PhD; Michael Messig, PhD; Alfred Callahan, MD; Michael Hennerici, MD, PhD; Henrik Sillesen, MD, MSc; K. Michael A. Welch, MB, ChB; on behalf of the SPARCL Investigators Background and Purpose In SPARCL, treatment with atorvastatin 80 mg daily reduced stroke risk in patients with recent stroke or TIA and no known coronary heart disease by 16% versus placebo over 4.9 years of follow-up. The purpose of this secondary analysis was to determine whether men and women similarly benefited from randomization to statin treatment. Methods The effect of sex on treatment-related reductions in stroke and other cardiovascular outcomes were analyzed with Cox regression modeling testing for sex by treatment interactions. Results (n 1908) constituted 40% of the SPARCL study population. At baseline, men (n 2823) were younger ( versus years), had lower systolic BPs ( versus mm Hg), higher diastolic BPs ( versus mm Hg), more frequently had a history of smoking (73% versus 38%), and had lower total cholesterol ( versus mg/dl) and LDL-C levels ( versus mg/dl) than women. Use of antithrombotics and antihypertensives were similar. After prespecified adjustment for region, entry event, time since event, and age, there were no sex by treatment interactions for the combined risk of nonfatal and fatal stroke (treatment Hazard Ratio, HR 0.84, 95% CI 0.68, 1.02 in men versus HR 0.84, 95% CI 0.63, 1.11 in women; treatment sex interaction P 0.99), major cardiac events (HR 0.61, 95% CI 0.42, 0.87 in men versus HR 0.76, 95% CI 0.48, 1.21 in women; P 0.45), major cardiovascular events (HR 0.78, 95% CI 0.65, 0.93 in men versus HR 0.84, 95% CI 0.65, 1.07 in women; P 0.63), revascularization procedures (HR 0.50, 95% CI 0.37, 0.67 in men versus HR 0.76, 95% CI 0.46, 1.24 in women; P 0.17), or any CHD event (HR 0.54, 95% CI 0.41, 0.72 in men versus % CI 0.46, 0.98 in women; P 0.40). Conclusion Stroke and other cardiovascular events are similarly reduced with atorvastatin 80 mg/d in men and women with recent stroke or TIA. (Stroke. 2008;39: ) Key Words: stroke TIA prevention lipids statins sex Meta-analysis of 14 trials of statins including more than subjects, most of whom had coronary heart disease (CHD) or major CHD risk factors, found men and women had similar treatment-associated reductions in both major coronary events and major vascular events. 1 Consistent with these results, the Prospective Pravastatin Pooling Project and the Heart Protection Study found statin treatment was associated with similar reductions in the occurrence of predominately first strokes regardless of sex. 2,3 A secondary analysis of subjects with CHD enrolled in 3 clinical trials of oral glycoprotein IIb/IIIa inhibitors found no significant difference in statin-associated stroke reductions between men and women. 4 Whether statin treatment is equally effective for secondary stroke prevention in men and women has not been addressed. The Stroke Prevention with Aggressive Reductions in Cholesterol Levels (SPARCL) trial showed that treating patients with recent stroke or TIA and no known coronary heart disease with a statin (atorvastatin 80 mg per day) reduced the combined risk of fatal and nonfatal stroke as well as other cardiovascular events. 5 The purpose of this post hoc analysis of data from the SPARCL trial was to determine whether men Received December 31, 2007; accepted January 28, From Duke University and VA Medical Centers (L.B.G.), Durham, NC; Denis Diderot University (P.A.), Paris; the University of Maryland (M.L.), Baltimore, Md; Rho Inc (S.G.), Newton, Mass; Pfizer, (M.M..) New York; Neurologic Consultants (A.C.), Nashville, Tenn; the University of Heidelberg (M.H.), Mannheim, Germany; the University of Copenhagen (H.S.), Denmark; and Rosalind Franklin University of Medicine and Science (K.M.A.W.), North Chicago, Ill. Correspondence to Larry B. Goldstein, Box 3651, Duke University Medical Center, Durham, NC golds004@mc.duke.edu 2008 American Heart Association, Inc. Stroke is available at DOI: /STROKEAHA
2 Goldstein et al Gender and Statin Effects in SPARCL 2445 and women similarly benefited from randomization to statin treatment. Methods The methods of the SPARCL study have been described in detail previously. 5,6 The local research ethics committee or institutional review board at each participating study center approved the study protocol, and all patients gave written informed consent. The primary hypothesis of the SPARCL trial was that treatment with 80 mg of atorvastatin per day would reduce the combined risk of fatal and nonfatal stroke among patients with a history of stroke or TIA. Eligible patients were men and women over 18 years of age who had had an ischemic or hemorrhagic stroke or a TIA (diagnosed by a neurologist within 30 days after the event) 1 to 6 months before randomization. Stroke was defined by focal clinical signs of central nervous system dysfunction of vascular origin that lasted for at least 24 hours; TIA was defined by the loss of cerebral or ocular function for less than 24 hours. Patients had to be ambulatory, with a modified Rankin score of no more than 3 (scores can range from 0 to 5, with higher scores indicating more severe disability), and to have an LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter) and no more than 190 mg per deciliter (4.9 mmol per liter; 15 of 205 centers excluded otherwise suitable patients with an LDL cholesterol level above 160 mg per deciliter [4.1 mmol per liter], as required by their institutional review boards). Excluded patients otherwise included those with atrial fibrillation, mechanical prosthetic heart valves, severe mitral valve stenosis, or subarachnoid hemorrhage. Patients with hemorrhagic stroke (2% of the study population) could be included if they were deemed by the investigator to be at risk for ischemic stroke or coronary heart disease. Subjects were enrolled between September 1998 and March The primary outcome for the SPARCL trial was the time from randomization to a first nonfatal or fatal stroke. There were 7 prespecified secondary composite outcomes: stroke or TIA; major coronary event (cardiac death, nonfatal myocardial infarction [MI] or resuscitated cardiac arrest); major cardiovascular event (stroke plus any major coronary event); any CHD event (major coronary event, plus coronary revascularization procedure, unstable angina or angina/ischemia requiring emergent hospitalization); revascularization procedure (coronary, carotid or peripheral); and any cardiovascular event (any of the former plus clinically significant peripheral vascular disease). An independent end point committee adjudicated all potential end points without knowledge of the patients treatment status or cholesterol levels. For this post hoc analyses, we evaluated the relative effects of intention to treat with atorvastatin 80 mg per day in men and women on the primary and each secondary SPARCL outcome in separate Cox regression models with prespecified adjustment for region (7 dummy variables), entry event, time since event, and age (each requiring 1 degree of freedom). Adjustment was made in the regression models for potential confounding by inclusion of covariates. A second set of analyses to control for additional possible confounders was performed to validate the primary analysis by using a logistic regression model to reduce the dimensionality of the data (a logistic regression predicting sex was fitted to baseline covariates including age, days since qualifying event, type of qualifying event, geographic region baseline lipid levels, systolic and diastolic blood pressure, body mass index, smoking and hypertension history). 7 Because of sample size limitations, all potential covariates could not be directly added to the Cox regression models. 8 Because exploratory analyses revealed possible nonlinear relationships, the model was also allowed to fit the squared and square root transformed versions of the listed continuous variables based on a forward selection procedure. The resulting model had a c-statistic of The linear predictor from this model was then saved and grouped by quintile. The data were then stratified by sex and quintile of the linear predictor from the previous logistic regression. Patients who could not be included in the logistic regression model because of missing data were assigned to their own strata. This resulted in a total Table 1. Baseline Characteristics by Sex (n 2823) (n 1908) Age, y Systolic blood pressure, mm Hg Diastolic blood pressure, mm Hg Body-mass index, kg/m Entry Event Stroke 1997 (70.7) 1271 (66.6) Hemorrhagic 60 (2.1) 33 (1.7) Ischemic: small vessel 841 (29.8) 568 (29.8) Ischemic: large vessel 479 (17.0) 270 (14.2) Unknown 617 (21.9) 400 (21.0) TIA 824 (29.2) 636 (33.3) Unknown/missing data 2 (0.07) 1 (0.05) Time since entry event, days Risk factors Smoking status Current smoker 640 (22.7) 268 (14.1) Former smoker 1426 (50.5) 455 (23.9) History of hypertension 1662 (58.9) 1266 (66.4) History of diabetes mellitus 485 (17.2) 309 (16.2) Any prior statin therapy 71 (2.5) 49 (2.6) Concomitant therapy Aspirin or other anti-platelet drug 2465 (87.3) 1665 (87.3) ACE Inhibitor 812 (28.8) 538 (28.2) Calcium channel antagonist 414 (14.7) 295 (15.5) Beta blocker 422 (15.0) 414 (21.7) Angiotensin II antagonist 120 (4.3) 92 (4.8) Vitamin K antagonist, including warfarin 183 (6.5) 110 (5.8) Baseline Lipids, mean SE LDL-C, mg/dl HDL-C, mg/dl Total Cholesterol, mg/dl Triglyceride, mg/dl Apolipoprotein A1, mg/dl Apolipoprotein B, mg/dl *Continuous variables are summarized as means SE. **Categorical variables are summarized as count (percentage). of 12 strata. The data for all patients were then analyzed using a stratified Cox regression model with covariate terms for age, days since qualifying event, qualifying event, and geographic region. The SPARCL steering committee developed the study protocol with the sponsor and takes responsibility for the data and data analyses. Medpace (Cincinnati) managed all data. Medpace, Charles River Laboratories Clinical Services (Brussels), and the sponsor provided site monitoring throughout the study. A data and safety monitoring board with independent statistical support performed interim monitoring analyses for safety and efficacy. Results Table 1 compares baseline characteristics between men (n 2823) and women (n 1908). were younger, had lower systolic BP, higher diastolic BP, less frequently had a history of hypertension, and more frequently had a history of smoking.
3 2446 Stroke September 2008 Table 2. Baseline, End of Treatment, and Percent Change From Baseline Lipid Levels by Sex (n 922) also had lower total cholesterol, LDL-C, HDL-C, and Apolipoprotein A1 levels than women. Use of antithrombotics and antihypertensives were similar. Table 2 gives the mean percent change from baseline to the last study visit for each lipid measure for atorvastatin and placebo treated men and women. There were no sex-based treatment differences in lipid profiles between men and women (LDL-cholesterol, P 0.986; total cholesterol, P 0.452; HDL-cholesterol, P 0.126; triglycerides, P ; Apo A1, P 0.135; Apo B, P 0.955). Table 3 gives adjusted hazard ratios, Wald probability values, and treatment by sex interaction probability values for each of the SPARCL trial primary and secondary outcomes. The separate results for men and women were generated by removing the sex term from the model (since each model includes either all men or all women). and women had similar treatment-associated benefits for each study end point (ie, there were no significant treatment by sex interactions for (n 943) (n 1397) (n 1379) LDL cholesterol, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline Total cholesterol, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline HDL cholesterol, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline P value, mean % change Triglycerides, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline Apo A1, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline P value, mean % change Apo B, mg/dl Baseline, mean SE End of treatment, mean SE mean % change from baseline *Baseline values summarize only those patients who also had at least one postbaseline measurement. **P values are based on an analysis of covariance with terms for baseline value, treatment, sex and treatment by sex interaction. the combined risk of nonfatal and fatal stroke, nonfatal stroke, fatal stroke, stroke or TIA, major cardiac events, major cardiovascular events, revascularization procedures, or any CHD event). The treatment by sex interaction term for all cause mortality is marginally significant (P 0.06). The second set of analyses using Cox regression models with stratification to control for additional potential confounders provided almost identical results (data not shown). Table 4 gives safety data by treatment and sex. 80 mg per day was similarly tolerated in men and women. Discussion This analysis of data from the SPARCL trial found similar statin-related reductions in stroke and other cardiovascular events in men and women who had a recent stroke or TIA and no known coronary heart disease at the time of study enrollment. To reduce the chances of spurious associations in
4 Goldstein et al Gender and Statin Effects in SPARCL 2447 Table 3. Stroke and Cardiovascular Outcomes and All-Cause Mortality by Sex Event Sex Subgroup n/n (%) (%) n/n (%) Adjusted Hazard Ratio (Wald 95% CI) Wald P Value Treatment X Sex Interaction P Value Any stroke All subjects 265/2365 (11.2) 311/2366 (13.1) 0.84 (0.71,0.99) /1427 (12.3) 204/1396 (14.6) 0.84 (0.68,1.02) /938 (9.5) 107/970 (11.0) 0.84 (0.63,1.11) 0.21 Fatal stroke All subjects 24/2365 (1.0) 41/2366 (1.7) 0.57 (0.34,0.95) /1427 (1.3) 24/1396 (1.7) 0.71 (0.38,1.31) /938 (0.6) 17/970 (1.8) 0.37 (0.14,0.93) 0.03 Nonfatal stroke All subjects 247/2365 (10.4) 280/2366 (11.8) 0.87 (0.73,1.03) /1427 (11.4) 186/1396 (13.3) 0.85 (0.69,1.05) /938 (9.0) 94/970 (9.7) 0.90 (0.67,1.21) 0.47 Stroke or TIA All subjects 375/2365 (15.9) 476/2366 (20.1) 0.77 (0.67,0.88) /1427 (16.3) 298/1396 (21.3) 0.75 (0.63,0.89) /938 (15.2) 178/970 (18.4) 0.81 (0.65,1.00) 0.05 MCE All subjects 81/2365 (3.4) 120/2366 (5.1) 0.65 (0.49,0.87) /1427 (3.4) 78/1396 (5.6) 0.61 (0.42,0.87) /938 (3.4) 42/970 (4.3) 0.76 (0.48,1.21) 0.25 MCVE All subjects 334/2365 (14.1) 407/2366 (17.2) 0.80 (0.69,0.92) /1427 (15.1) 266/1396 (19.1) 0.78 (0.65,0.93) /938 (12.6) 141/970 (14.5) 0.84 (0.65,1.07) 0.15 Revascularization All subjects 94/2365 (4.0) 163/2366 (6.9) 0.55 (0.43,0.72) /1427 (4.6) 126/1396 (9.0) 0.50 (0.37,0.67) /938 (3.0) 37/970 (3.8) 0.76 (0.46,1.24) 0.27 Any CHD Event All subjects 123/2365 (5.2) 204/2366 (8.6) 0.58 (0.46,0.73) /1427 (5.5) 137/1396 (9.8) 0.54 (0.41,0.72) /938 (4.8) 67/970 (6.9) 0.67 (0.46,0.98) 0.04 All-cause mortality All subjects 216/2365 (9.1) 211/2366 (8.9) 1.00 (0.82,1.21) /1427 (10.2) 124/1396 (8.9) 1.14 (0.90,1.45) /938 (7.5) 87/970 (9.0) 0.78 (0.57,1.07) 0.12 Results reflect adjustment for region, entry event, time since entry event, and age. MCE indicates major cardiac event; MCVE, major cardiovascular event; CHD, coronary heart disease (see methods for description). this post hoc analysis, we tested treatment by sex interactions for the SPARCL primary end point (first occurrence of a nonfatal or fatal stroke) as well as for all of the study s prespecified secondary endpoints. This analysis is a combination of a randomized trial and an observational study (ie, randomized treatment effects and nonrandom subgroups defined by sex). In Table 3, the adjusted Table 4. SPARCL Safety by Sex hazard ratios by sex were obtained by running separate analyses on men and women controlling for age, qualifying event, days since qualifying event, and geographic region. Because treatment was randomized, these provide unbiased estimates of treatment effects for men and women. Other baseline variables such as age, baseline lipids, and blood pressure, however, differed between men and women (Table 1). To assure that any (n 938) (n 970) (n 1427) (n 1396) ALT/AST 3 ULN*, n (%) 13 (1.39%) 1 (0.10%) 8 (0.56%) 2 (0.14%) CPK 10 ULN*, n (%) 1 (0.11%) 0 1 (0.07%) 0 Musculoskeletal AEs Myalgia, n (%) 63 (6.7%) 72 (7.4%) 66 (4.6%) 69 (4.9%) Myopathy, n (%) 3 (0.3%) 2 (0.2%) 4 (0.3%) 5 (2.0%) Rhabomyolysis, n (%) 1 (0.1%) 2 (0.2%) 1 (0.1%) 1 (0.1%) *Persistent elevations: 2 consecutive elevations within 4 to 10 days. ALT indicates Alanine aminotransferase; ULN, upper limits of normal; CPK, creatine phosphokinase.
5 2448 Stroke September 2008 possible sex differences were not explained by differences in the baseline covariates, a second set of more complex analyses were performed with results not substantially different than those given in Table 3. It should be recognized, however, that the SPARCL trial was not designed to detect differences in event rates between men and women, and that statistical power of this analysis may be limited. As shown in Table 3, the treatment by sex interaction term for all cause mortality is marginally significant. Although a relative treatment-related reduction in all cause mortality in women as compared to men cannot be excluded, the individual treatment effects are not significant (HR 1.14, 95% CI 0.90 to 1.45, P 0.28 for men and HR 0.78, 95% CI 0.57 to 1.07, P 0.12 for women). The Heart Protection Study (HPS) compared the effects of simvastatin and placebo in a broad spectrum of patients that included 3280 subjects with prior cerebrovascular disease. 3 As in SPARCL, 5 the HPS found a reduction in major vascular events in patients with prior cerebrovascular disease treated with a statin, but in contrast to SPARCL, there was no reduction in recurrent stroke (and no analysis for a treatmentrelated difference in recurrent stroke based on sex). Some potential reasons for the difference between the trial results have been discussed previously and include later enrollment after the index event in HPS, smaller treatment-related reductions in lipid levels, and lack of power because of a small number of outcome strokes. 5 In HPS, there was not a specific analysis to determine whether the effects of the statin on the occurrence of major vascular events differed between men and women with prior stroke. 3 Several studies provide data assessing potential sex-related differences in the effects of statins for primary stroke prevention. The HPS found similar reductions in the frequencies of a first stroke with statin treatment in men and women. 3 At least 2 other randomized placebo-controlled statin trials have provided subgroup analyses of stroke outcomes stratified by sex. 4 The Cholesterol and Recurrent Events (CARE) study found a nonsignificant 35% reduction of stroke with statin treatment in women but no difference between men and women. 9 The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) study found that more women in the statin group (4.4%) than in the placebo group (3.6%) had strokes with a beneficial effect in men (3.6% with statin treatment versus 4.7% with placebo). 10 When the data from these 2 trials was pooled with data from the West of Scotland Coronary Prevention Study (WOSCOPS), there was no statistical interaction between sex and statin treatment on the occurrence of stroke events. 2 Therefore, there is no evidence for a sex-related difference in the effects of statins in primary stroke prevention in the setting of known coronary heart disease or in other primary prevention populations. There are several stroke risk factors that are unique to women, and new areas of research offer the possibility of developing preventive therapies aimed at reducing a woman s chances of having a first or recurrent stroke. 11 As reflected in the baseline data from the SPARCL trial, even traditional stroke risk factor profiles for men and women can differ. Despite these differences, this secondary analysis of SPARCL trial data suggests that statin treatment similarly reduces the likelihood of stroke and other cardiovascular events in men and women with recent TIA or stroke. Sources of Funding The SPARCL trial was funded by Pfizer. Employees of Pfizer contributed to the design and conduct of the SPARCL trial, the collection, management, analysis, and interpretation of the data, and reviewed the manuscript. Disclosures Larry Goldstein has received honoraria from Pfizer during the course of this study. The honoraria did not exceed $10 000/yr. Pierre Amarenco has received grants from Pfizer for other research or activities not reported in this research exceeding $10 000/yr and honoraria from Pfizer in excess of $10 000/yr during the course of this study. Marian LaMonte declares no conflicts aside from participation as a site investigator in the SPARCL trial. Steven Gilbert is employed by Rho Inc, a company that provides statistical consultation for Pfizer. Michael Messig is an employee of Pfizer and owns Pfizer stock. Alfred Callahan has received research support and honoraria from Pfizer in excess of $10 000/yr during the course of this study. Michael Hennerici has received grants from Pfizer for other research or activities not reported in this research/article and honoraria from Pfizer during the course of the study. Neither the grants nor the honoraria exceeded $10 000/yr. Henrik Sillesen has received grants from Pfizer for other research or activities not reported in this research/article in excess of $10 000/yr and honoraria exceeding $10 000/yr during the course of this study. K. Michael Welch has received honoraria from Pfizer during the course of the study in excess of $10 000/yr and research support less than $10 000/yr. References 1. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from participants in 14 randomised trials of statins. Lancet. 2005;366: Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103: Heart Protection Study Collaborative Group. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363: Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355: The SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Cerebrovascular Diseases. 2003;16: Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79: Harrell F, Lee K, Mark D. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat in Med. 1996;15: Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol and Recurrent Events (CARE) study. Circulation. 1999;99: LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pavastatin in Ischaemic Disease (LIPID) study group. N Engl J Med. 1998;339: Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MSV, Stern B, Herrington D, Ford-Lynch G, P. G., James A, Brown CM, Choi E, Bray P, Newby LK, Goldstein LB, Simpkins J. Advancing the study of stroke in women. Summary and recommendations for future research from an NINDS-sponsored multidisciplinary working group. Stroke. 2006;37:
LDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationSupplementary Online Content
Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationGame Strategy: High Intensity Statin in Stroke. K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018
Game Strategy: High Intensity Statin in Stroke K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018 No Disclosures Are you Mind Full or Mindful? Objectives 1. Discuss the correlation between
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationThe Effect of Statin Therapy on Risk of Intracranial Hemorrhage
The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy
More informationPresented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer
Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationStatins and stroke prevention
Acta neurol. belg., 2003, 103, 13-18 Statins and stroke prevention P. LALOUX Service de Neurologie, Cliniques Universitaires de Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium Key words
More informationA bs tr ac t. n engl j med 357;15 october 11,
The new england journal of medicine established in 1812 october 11, 2007 vol. 357 no. 15 Long-Term Follow-up of the West of Scotland Coronary Prevention Study Ian Ford, Ph.D., Heather Murray, M.Sc., Chris
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationHeart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationLipids management and prevention of Stroke
Lipids management and prevention of Stroke Dr.Vamshi Mallavarapu MD, FACC,RPVI Director CCU, Abington Hospital-Jefferson Health Diplomat of American Board of Clinical Lipidology None Disclosures Objectives
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationCardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
Journal of the American College of Cardiology Vol. 61, No. 2, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.042
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationCholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation
TrialResults-center.org www.trialresultscenter.org Cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation A systematic review and
More informationJ-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial
J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary Background
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationEpidemiology and Prevention of Stroke
Copyright Information Copyright protected material has been deleted from this presentation. References to the deleted material are provided for each slide. Epidemiology and Prevention of Stroke Larry B.
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationSession : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION
Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationFlaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials
Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationPitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age
Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age Craig A. Sponseller, Masaya Tanahashi, Hideki Suganami,
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationCoronary Heart Disease
Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationSlide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure
Slide 1 The Treatment of Intracranial Stenosis Helmi Lutsep, MD Vice Chair and Dixon Term Professor, Department of Neurology, Oregon Health & Science University Chief of Neurology, VA Portland Health Care
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationYork, New York, USA. Received 22 March 2010 Revised 5 October 2010 Accepted 17 November 2010
592 Original article Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm David J. Collier a, Neil R. Poulter b, Björn Dahlöf c, Peter
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationCanagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationImproved control for confounding using propensity scores and instrumental variables?
Improved control for confounding using propensity scores and instrumental variables? Dr. Olaf H.Klungel Dept. of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More information